Related Experiment Video
Updated: Feb 7, 2026

Whole-cell Currents Induced by Puff Application of GABA in Brain Slices
Published on: October 12, 2017
GABA and Artesunate Do Not Induce Pancreatic α-to-β Cell Transdifferentiation In Vivo
Amanda M Ackermann1, Nicholas G Moss2, Klaus H Kaestner3
1Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
Recent reports identified activation of the GABA signaling pathway as a means to induce transdifferentiation of pancreatic α cells into β cells. These reports followed several previous studies that found that α cells were particularly well suited to conversion into β cells in mice, but only after nearly complete β cell loss or forced overexpression of key transcriptional regulators. The possibility of increasing β cell number via reprograming of α cells with a small molecule is enticing, as this could be a potential new pharmacologic therapy for diabetes. Here, we employed rigorous genetic lineage tracing of α cells, using Glucagon-CreERT2;Rosa-LSL-eYFP mice, to evaluate if activation of GABA signaling caused α-to-β cell reprogramming. In contrast to previous reports, we found that even after long-term treatment of mice with artesunate or GABA, neither α-to-β cell transdifferentiation nor insulin secretion were stimulated, putting into question whether these agents represent a viable path to a novel diabetes therapy.
Insights
Activating GABA signaling does not convert pancreatic alpha cells to beta cells. This study questions the potential of GABA signaling agents as a new diabetes therapy, as they did not stimulate cell reprogramming or insulin secretion.
Area of Science:
- Endocrinology
- Cell Biology
- Diabetes Research
Background:
- Pancreatic alpha cells can potentially be reprogrammed into beta cells.
- Previous studies suggested GABA signaling activation could induce this transdifferentiation, particularly after beta cell loss.
- Small molecule-driven alpha-to-beta cell reprogramming offers a potential therapeutic strategy for diabetes.
Purpose of the Study:
- To rigorously evaluate if activating the GABA signaling pathway induces alpha-to-beta cell transdifferentiation.
- To assess the therapeutic potential of GABA signaling agents for increasing beta cell mass.
Main Methods:
- Utilized genetic lineage tracing in Glucagon-CreERT2;Rosa-LSL-eYFP mice.
- Administered artesunate or GABA long-term to mice.
- Monitored for alpha-to-beta cell reprogramming and insulin secretion.
Main Results:
- Long-term treatment with artesunate or GABA did not induce alpha-to-beta cell transdifferentiation.
- No stimulation of insulin secretion was observed following GABA signaling activation.
- Findings contradict previous reports on GABA-induced cell reprogramming.
Conclusions:
- Activation of GABA signaling is not sufficient to reprogram pancreatic alpha cells into beta cells.
- Artesunate and GABA do not appear to be viable pharmacologic agents for diabetes therapy via cell reprogramming.
- The efficacy of targeting GABA signaling for diabetes treatment requires further investigation.
More Related Videos
07:04Author Spotlight: Assessment of Mitophagy Flux in Pancreatic β-Cells Using Effective and Robust Complementary Approaches
Published on: September 15, 2023
11:57Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking
Published on: March 28, 2014
Related Concept Videos
Forced Transdifferentiation
Artificial...
Conjugate Addition to α,β-Unsaturated Carbonyl Compounds
Cell Specific Gene Expression
Induced Pluripotent Stem Cells
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
α-Alkylation of Ketones via Enolate Ions